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ABSTRACT
Progressive accumulation of collagen and extracellular matrix (ECM) proteins within
renal glomeruli have implications for or result in renal fibrosis and glomerulosclerosis,
with both events culminating in renal failure. To model this accumulation the Col1a2deficient mouse model was used. The Col1a2-deficient mouse model is characterized by
a mutation in the a2(I) chain, preventing incorporation into the type I collagen molecule.
As a result, an α1(I) collagen chain incorporates into the collagen triple helix forming
homotrimeric type I collagen, as opposed to heterotrimeric type I collagen. This change is
due to the secondary wound healing response in response to ECM accumulation, fibrosis,
or damage. Transforming growth factor-beta (TGF-β) has been studied within this model
and demonstrated it was not the initiating molecule in collagen deposition. This study
looks at Tumor Necrosis Factor-Alpha (TNF-a) and Platelet Derived Growth Factor
(PDGF) as potential mediators of this hypothesized secondary wound healing response.
TNF-a is an inflammatory cytokine produced following tissue damage, released by
mesangial cells, and has been shown to induce epithelial-to-mesenchymal transition
(EMT). Recently, PDGF receptors and ligand upregulation has been shown in other
mouse models of renal fibrosis. However, TNF-a showed no differential staining upon
Picrosirius Red (PSR) between experimental and control groups. PDGFR-ββ and PDGFBB displayed differential labeling in Col1a2-deficient in comparison to age matched wild
type animals. The results for PDGF-DD mice were less conclusive when comparing the
Col1a2-deficient mice to that of their wild type counterparts.
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INTRODUCTION

Clinical Significance
A Center for Disease Control (CDC) report from 2017 found morbidity rates from
chronic kidney disease (CKD) estimated at 30 million. This indicated that 15% of the
United States adult population is suffering from some form of CKD. 96% of individuals
living with mild CKD are unaware of this disease.1.Risk factors for developing CKD
include: diabetes, high blood pressure, high fat diet, smoking, and others.2 Signs and
symptoms of CKD include: nausea, loss of appetite, vomiting, fatigue or weakness,
change in frequency of urination, muscle twitches or cramps, chest pain, shortness of
breath, high blood pressure, and many more. However, these signs normally present after
it is too late to reverse the effects of CKD.2
Many complications can arise from having CKD, for example, an increase in
heart and blood vessel disease.1 In addition, anemia, fluid retention (swelling), an
increase in potassium levels (hyperkalemia), reduced immune response, and others are
also complications associated with CKD.2 However, these complications can be avoided
by selecting wise food options. Eating food with less potassium, less added salt, and less
phosphorous can all help in reducing chances of developing CKD.2 However, if a patient
does present with CKD there are treatment options to improve health. Medication is one
route, this includes medication for: blood pressure, cholesterol, anemia, and increase in
fluid (swelling). Calcium and vitamin D supplement may be given if bone integrity is
affected.2
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CKD is progressive and ultimately will develop into End Stage Renal Disease
(ESRD). The full manifestation of both of these diseases is renal failure. Development of
renal failure results in dialysis treatment and kidney transplantation.1 CKD and ESRD is
very expensive to treat and places a large burden on Medicare. The estimated cost of
treating patients with CKD and ESRD in America, as reported by the United States Renal
Data System (USRDS), is 100 billion dollars per year. 64 billion of these dollars are
being used to treat individuals with CKD, and another 34 billion are being used for
patients with ESRD. The combined costs of CKD and ESRD alone make this an urgent
issue in the United States.3
Studying fibrosis and kidney disease utilizes the use of mouse models. In this
study, the Col1a2-deficient mouse model was used.
Collagen and Col1a2-deficient Mouse Model
Originally, the Col1a2-deficient was termed osteogenesis imperfecta model, as it
was used to study musculoskeletal malformations within mice.4 A decrease in bone
integrity characterizes COL1A1/2-related osteogenesis imperfecta with four distinct
varieties. The bones of individuals are highly brittle and can fracture with little to no
trauma.5 However, for this study, the Col1a2-deficient mouse model is being used to
study homotrimeric type I collagen glomerulopathy.
There are at least 16 types of collagen in the human body6, but type I collagen is
the most abundant.7 Collagen is a structural protein seen in the extracellular matrix
(ECM). It functions as a scaffolding protein for blood vessels throughout the body, makes
up a large percentage of bone density, and is involved in the secondary wound healing
response to repair tissue damage. Type I collagen starts out as proa2 and proa1 chains.
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These chains have their carboxy-peptide regions cleaved which allows the chains to
incorporate into a helix conformation.8 Resulting in collagen transforming from a procollagen to mature collagen form. Type I collagen is a triple helix composed of three
interacting alpha chains and exists naturally in two isotypes (Figure 1). The most
abundant is the type I collagen heterotrimer composed of two a1 chains and an a2 chain.
These chains are synthesized as pro-collagen fibrils, proa1(I) and proa2(I) respectively
(Figure 2) and are encoded for by the COL1A1 and COL1A2 genes. Figure 2 illustrates
heterotrimeric type I collagen as a right handed triple helix. Each chain making up the
homotrimer is characterized by a Gly-Xaa-Yaa repeat, with glycine packed in the middle
of the right handed triple helix to coil heterotrimeric type I collagen.9
The COL1A1 gene is on the 11th chromosome and the COL1A2 gene is located
on the 6th chromosome in Mus musculus or mouse.10,11 The homotrimeric type I collagen
is composed, exclusively, of a1 chains. The type I collagen homotrimer is seen in very
small amounts physiologically, and is present in adult skin, embryological development,
and during the wound healing response.7
The COL1A2 mouse model is characterized by a homozygous mutation found
within the COL1A2 gene. Because of this, these mice synthesize mutated proa2(I) chains
that are unable to incorporate into the triple helix. This spontaneous mutation has resulted
in a DNA deletion within the carboxy-peptide encoding region. This spontaneous
mutation is responsible the loss of interaction between the a2 chain and its a1 chain
counterparts.7 Since the a2 chains are not incorporated into type I collagen, they are
replaced with an a1 chain, thereby, producing homotrimeric type I collagen.12 The
Col1a2-deficient mouse model exclusively synthesizes homotrimeric type I collagen in
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the homozygous affected mice. Type I collagen, specifically the homotrimer, is deposited
in the mesangial matrix of glomeruli in these Col1a2-deficient mice.7
A negative feedback mechanism controls synthesis of the COL1A2 and COL1A1
genes through the cleavage of the proa2(I) carboxy-peptide region, the area responsible
for interaction between a2 and a1 chains. Upon cleavage there is a translocation of this
proa2 carboxy-peptide region to the nucleus where it downregulates the transcription of
not only the COL1A2 gene, but also the COL1A1 gene.8 Cleavage of the carboxy-peptide
region has been shown to decrease the assembly of collagen. The mutation in the
carboxy-peptide region of the proa2(I) within the Col1a2-deficient mouse model no
longer allows this cleavage to occur, this suggests that the carboxy-peptide cleavage
deficiency within the a2 chain could allow an overproduction of the homotrimeric type I
collagen isotype.13 However, overproduction of collagen could also be due to a decrease
in the degradation of homotrimeric type I collagen by matrix metalloproteinases (MMPs).
Recent studies have shown that heterotrimeric type I collagen is more vulnerable
to degradation than homotrimeric type I collagen. Homotrimeric type I collagen is
actually said to be resistant to degradation by MMPs.14 It was hypothesized that not only
an increase in synthesis of homotrimer but also a decrease in degradation of the
homotrimer is contributing to the pathology of homotrimeric type I collagen
glomerulopathy in the Col1a2-deficient mice.7
The COL1A2 mouse model offers an excellent way to study homotrimeric type I
collagen and its effects within the kidney. Comparison of Col1a2-deficient mice and wild
type mice help characterize the role of homotrimeric type I collagen in wild type vs.
Col1a2-deficient mice. Lastly, the Col1a2-deficient mouse model will help define the
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role of a2(I) chains functionality in collagen.4
Glomerular Structure and Development
Collagen deposition, seen within the Col1a2-deficient mouse model, occurs in the
glomeruli of the kidneys. Glomeruli are composed of mesangial cells, epithelial cells,
referred to as podocytes, and endothelial cells. Endothelial cells form a boundary between
blood vessels and tissue, however, glomerular endothelial cells are more specialized.
They are highly fenestrated with the fenestrations making up 30-50% of their overall
surface area. Glomerular endothelial cells have a role in the ability of nephron to produce
filtrate at such an efficient rate.17 The fenestrations of endothelial cells are equivalent to
the filtration slits created by podocytes. Epithelial cells, i.e. podocytes, are found attached
to glomerular capillaries. Podocytes interdigitate with one another to form filtration slits
contributing to the efficiency of ultrafiltrate production.18 Mesangial cells comprise
greater than 30-40% of the entire glomerulus.19 Mesangial cells have various functions
from phagocytosis, removing debris from filtration to slits, aiding in maintenance of the
glomerular filtration rate (GFR), and their ability to produce extracellular matrix (ECM)
proteins. ECM proteins include collagen, elastin, fibronectin, and laminin.20 ECM
proteins are responsible for cellular scaffolding and formation of the glomerular
basement membrane.21 A cross section of a glomerulus is provided (Figure 3) and shows
the different cells type and their organization within the Bowman’s capsule. A Bowman’s
capsule houses an individual glomerulus and is connected to the tubular system.
Glomeruli are what allow the functional unit of the kidney, the nephron (Figure 4), to
filter blood and produce urine.
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Figure 1. Heterotrimeric and Homotrimeric Type I Collagen.
Type I collagen exists as two isotypes; heterotrimeric and homotrimeric type I collagen.
The heterotrimer seen in greater abundance throughout the body and is made up of one
a2(I) chain and two a1(I) chains. The homotrimer is seen in wound healing and
embryological development. The homotrimer is madeup of three a1(I) chains. Figure
created by Amanda Brodeur, MD/PhD.
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Figure 2. Structure of Collagen.
Type I collagen is a heterotrimer composed of two α1 and one α2 left-handed
polyproline II-like chains that are assembled into a right-handed triple helix. It is
synthesized as a procollagen, containing both amino-terminal and carboxyl-terminal
propeptide sequences, which are proteolytically cleaved by specific proteases (a
disintegrin and metalloproteinase with thrombospondin motifs 2 (ADAMTS2) and
bone morphogenetic protein 1 (BMP1), respectively) that recognize a sequence in the
telopeptides, that is, p.Pro161Gln162 in α1(I) and p.Ala79Gln80 in α2(I) for the Nterminal cleavage sites, and p.Ala1218Asp1219 and p.Ala1119Asp1120 for the Cterminal cleavage sites.15 The sequence of each collagen chain is characterized by GlyXaa-Yaa repeats (in which X and Y can be any amino acid (AA) but are most often
proline and hydroxyproline). Glycine is required at every third position and is tightly
packed at the center of the triple helical structure. Collagen contains ∼20% proline
residues. The post-translational 4-hydroxylation of most prolines in the Yaa position is
required for triple helical stability.16 Along the α1-chain, specific regions that are
relevant for the interaction of collagen with other collagen molecules or with
extracellular matrix proteins were identified, namely, major ligand-binding region
(MLBR).9
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Collagen is an important protein in renal function. Type 4 collagen is the primary
component of the basement membrane; however, in this study, type I collagen is the
collagen of interest and is found supporting vasculature in healthy kidney, no collagen is
found within glomeruli. However, type I collagen has been seen to be synthesized upon
renal injury or damage to the glomerulus. Furthermore, cultured mesangial cells have
been shown to produce ECM, primarily type I collagen, but also, types III, IV, and V
collagens.20.
Mice are born with numerous (2,000-2,50022) glomeruli at birth, but these
glomeruli are not all functional. The glomeruli follow a development timeline from day
zero to day 21. Glomeruli first develop in the juxtamedullary region and then develop in a
centrifugal pattern outward towards the cortex.23-25 The glomeruli in the cortex fully
develop at day 21. Humans and other mammals exhibit a similar centrifugal development
pattern.25-27.
Characterization of Type I Collagen Glomerulopathy
Homogenous material was present in renal glomeruli of Col1a2-deficient mice
when analyzed histologically.7 Picrosirius Red (PSR) was used to evaluate if this
accumulation was indeed collagen. Glomeruli from Col1a2-deficient mice stained
positive for PSR, showing that type I or type III collagen was present in the glomeruli of
Col1a2-deficient mice.4 It was also shown that heterozygous animals had small amounts
of PSR positive glomeruli (Figure 5). Electron microscopy (EM) was used to further
localize the deposition of collagen in the glomerulus. EM showed that collagen had been
deposited in the renal mesangium.7 It was unknown if type I or type III collagen was
deposited in the renal mesangium, antibody labeling was used to detect the proa1(I)
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Figure 3. Medullary Section of Kidney Structure.
Kidneys contain approximately twelve medullary regions and each region has numerous
nephrons woven throughout the cortex and medullary pyramid. The Bowman’s capsule
housing the glomerulus is found in the cortical region along with the Proximal
Convoluted Tubule (PCT) and Distal Convoluted Tubule (DCT). The Loop of Henle
extends into the salty medullary region where water is taken out of the tubule network
and resorbed into the tissue. The nephron is the main urine filtration unit.28
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Figure 4. Cross Section and Internal Structure of a Glomerulus.
Filtration takes place, initially, in the glomerulus. The glomerulus is comprised of three
major cell types: mesangial, epithelial, and endothelial. The mesangial cells are seen in
the middle of the image in green with purple nuclei. The visceral epithelium (podocytes)
are seen in light blue along with their foot processes that interdigitate with one another.
and capillary loops are seen as open spaces surround by fenestrated endothelium in
orange. The basement membrane is seen in dark pink and finally the Bowman’s capsule
is seen in yellow and is made up of parietal epithelium.29
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chain and the proa1(III) chain. Immunohistochemistry (IHC) showed antibody labeling
for the proa1(I) chain and not the proa(III) chain indicating that the homogenous
material accumulated in the renal mesangium was in fact type I collagen.4
Further study demonstrated that heterozygous animals were affected in a gene
dose dependent manner.14 The deposition of type I collagen occurred early within the
development process, as early as one-week of age in the juxtamedullary region. In
addition, at the end of glomerular development, around one month of age there was
collagen deposited in glomeruli in all regions of the kidney (Figure 6). Approximately
55% of all glomeruli in Col1a2-deficient mice were affected in mice two weeks of age in
comparison to only 8% of glomeruli in heterozygous mice. At the end of glomerular
maturation, one-month of age, PSR positive staining was present in 95% of Col1a2deficient mice in comparison to 54% of heterozygous mice (Figure 7). The pattern of
collagen deposition followed glomerular maturation. Collagen is first deposited in the
glomeruli located in the juxtamedullary region followed by the cortical region at onemonth (Figure 8). It was also shown that the type I collagen glomerulopathy was
progressive with age.7
Electron microscopy further showed the extent of collagen deposition and
exhibited collagen deposition in the mesangial matrix and in the subendothelial spaces,
increasing the distance between endothelial cells and the glomerular basement
membrane. Podocyte effacement was also observed potentially affecting the integrity of
the glomeruli (Figure 9). Podocyte effacement is characterized by the fusion or retraction
of podocyte foot processes.25 Podocyte effacement paired with proteinuria is indicative
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that collagen deposition is leading to glomerular injury and impairment of renal
function.7
Albumin and creatinine levels were analyzed to determine if the collagen
deposition had pathologic significance. A mean of 38.19 µg albumin/mg creatinine for
Col1a2-deficient mice was observed, compared to 0.50 µg albumin/mg creatinine for
wild type mice (Table 1).7
Deficient Degradation of Homotrimeric Type I Collagen
To prove that Col1a2-deficient mice were only making homotrimeric collagen
and to determine which isotype of type I collagen was deposited in heterozygous mice,
immunohistochemical analysis of a1(I) and a2(I) was performed. IHC analysis revealed
that a1(I) and a2(I) were present in the vasculature of the wild type mice, however, no
a2(I) antibody was present within the glomeruli of the heterozygous and homozygous
mice. In contrast, a1(I) chain was present in glomeruli of both heterozygous and
homozygous Col1a2-deficient mice (Figure 10).14
To determine if the deposition of homotrimeric type I collagen was in response to
increased proa1(I) and proa2(I) gene expression, whole kidneys were analyzed via RTPCR from all three genotypes of mice: wild type, heterozygous, and homozygous
affected. Different age groups were evaluated, one-week, two-weeks, and one-month of
age. mRNA levels for proa1(I) were higher in Col1a2-deficient mice at one month in
comparison to wild type and heterozygous mice. This was further confirmed as glomeruli
isolations from these mice were evaluated via RT-PCR and showed similar findings to
that of the whole kidney isolates (Figure 11).14 Based on IHC it would be expected that
COL1A1 mRNA would increase in heterozygous animals, however, this increase was not
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Figure 5. Deposition of type I collagen in heterozygous and Col1a2-deficient
glomeruli. Picrosirius red-stained sections of (a) wild type (lesion score 0), (b)
heterozygous (lesion score 1), and (c) Col1a2-deficient (lesion score 4) kidneys from 1month-old mice. Arrows indicate glomeruli. Asterisks denote affected (Picrosirius red+)
glomeruli.7
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Figure 6. Initiation of type I collagen deposition in glomeruli occurs postnatally.
Picrosirius red stain of (a, d, and g) 1-day-old, (b, e, and h) 2-week-old, and (c, f, and i)
1-month-old mice. (a–c) Wild-type (+/+) mice do not demonstrate collagen deposition
and have lesion scores of 0. (d–f) Heterozygous (+/-) mice show evidence of disease at 2
weeks (inset: enlargement of indicated glomeruli (e)), demonstrating lesion scores of 0 at
1 day, 1 at 2 weeks, and 1 at 1 month. (g–i) Col1a2-deficient (-/-) mice also show
evidence of deposition at 2 weeks with a lesion score of 0 at 1 day, 1 at 2 weeks, and 4 at
1 month. Arrows indicate glomeruli. Asterisks denote affected (Picrosirius red+)
glomeruli.7
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Figure 7. The type I collagen glomerulopathy in heterozygous mice demonstrate a
gene dose effect (*P<0.0001) that is progressive with age (**P<0.0001). The percent
of affected glomeruli per field is significantly greater in Col1a2-deficient (-/-) than
heterozygous (+/-) kidneys at both 2 weeks and 1 month of age. Significant differences in
the percent of glomeruli affected between kidneys examined at 2 weeks and 1 month of
age is also shown irregardless of genotype.7
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Figure 8. The type I collagen glomerulopathy initiates postnatally and glomeruli
sequentially become affected in a centrifugal pattern from the juxtamedullary (jm)
to the cortical (c) region in a distribution consistent with glomerular maturation and
initiation of function. (a) Demonstrates that there is a significant difference between the
morphometry score in jm and c glomeruli at 2 weeks and 1 month of age in Col1a2deficient mice with more severely affected glomeruli located in the jm region where
glomerular function initiates. (b) Demonstrates a significant difference between percent
of glomeruli affected per field between jm and c glomeruli in Col1a2-deficient mice at 2
weeks of age whereas greater than 90% of jm and c glomeruli per field are affected by 1
month of age. Conversely, the heterozygous animals lack a significant difference at the
earlier time point but demonstrate a significant difference in both lesion severity and
percent glomeruli affected per field between jm and c glomeruli at 1 month of age.
Further, the lesion severity and percent glomeruli affected is significantly different
between the 2 week and 1 month ages (§), confirming the progressive nature of the
glomerulopathy (*P<0.05, **P<0.005, ***P<0.0001).7.
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Figure 9. Electron Microscopy of Glomeruli from Wild Type and Col1a2-deficient
Mice. (a) Electron microscopy of glomeruli from wild-type and (b and c) Col1a2deficient mice (lesion score 4) demonstrate that the Col1a2-deficient glomeruli exhibit
deposition of extracellular fibrillar type I collagen (c) into the subendothelial space
displacing the fenestrated endothelium (e) from the underlying glomerular basement
membrane (b). Fibrils demonstrating cross striation of organized collagen (b; inset) were
also present. In areas of severe collagen deposition and expansion of the subendothelial
space, podocyte (p) foot process effacement is seen (c). It is hypothesized that the type I
collagen is being produced by the mesangial (m) cell followed by deposition in the
subendothelial space. In all mice examined, the glomerular basement membrane (GBM)
was intact. Wild-type provided for comparison (a).7
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Table 1. Col1a2-deficient mice demonstrate albuminuria in comparison to wild type
animals.7
Genotype

n

Albumin (µg)/creatinine (mg)(range)

Wild-type

12

0.50±0.14 (0.06-1.43)

Col1a2-deficient

14

38.19±12.33* (0.41-128.55)

0

12

0.50±0.14

1

1

0.41

2

4

8.91±6.53**

3

6

42.27±20.63*

4

3

81.65±25.15*

Lesion Score

** P<0.0001
* P<0.005

18

found to be the primary mechanism of type I collagen glomerulopathy. Therefore, it is
suggested that a decrease in degradation of collagen may be the cause type I collagen
glomerulopathy.
Deficiency in the degradation of homotrimeric type I collagen in the Col1a2deficient may be leading to the deposition. Matrix metalloproteinases (MMPs) are
responsible for the regulation of the ECM, thereby, the degradation of collagen
accumulation. MMP 2, 3, 9, and 13 are expressed in the kidney and have the ability to
cleave type I collagen. There was an upregulation of mRNA for MMP 2,3, and 9 at three
months of age in Col1a2-deficient mice and there was no change in that of the
heterozygous mice (Figure 12. A-C). MMP 13 is responsible for targeting and cleaving
the a2(I) chain and was not elevated in the Col1a2-deficient mouse model.14
It was further shown that MMP 2 and MMP 3 were both elevated at one month for the
Col1a2-deficient mice (Figure 12. D&E).14 In order for MMPs to be responsible for this
event, mRNA would have to increase before an increase in collagen deposition, however,
this was not seen. It was concluded that MMPs were not the primary event leading to the
pathology of homotrimeric type I collagen deposition in this model.14
Therefore, MMPs may play a role in the pathology of the Col1a2-deficient mouse
model but are not the primary mediator of homotrimeric type I collagen deposition.
Investigation into what initiates the type I collagen deposition was then pursued.
Investigation into the Potential Role of TGF-b in Col1a2-deficient Mice
The renal mesangium comprises greater than 30% of the total glomerulus. In this
location mesangial cells reside and are mediators of the wound healing response. In
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Figure 10. Identification of type I collagen homotrimer in wildtype (+/+) (A,D,G,J),
heterozygous (+/−) (B,E,H,K) and homozygous (−/−)(C,F,I,L) glomeruli. Picrosirius
red (PSR) staining under normal (A,B,C)and polarized light (D,E,F) of wildtype
glomeruli (A,D) show no deposition of type I collagen, heterozygous glomeruli (B,E)
show mild deposition of type I collagen, and homozygous glomeruli (C,F) show severe
deposition of collagen within glomeruli. Anti- α1(I) collagen immunohistochemistry
(IHC)(G–I) of wildtype kidneys (G) demonstrate no localization of α1(I) chains within
glomeruli, only in the vasculature. Heterozygous kidneys (H) show localization of type I
collagen α1(I) chains within the glomeruli and vasculature. Homozygous kidneys (I)
mice also show evidence of type I collagen α1(I) in the glomeruli and vasculature. Antiα2(I) collagen IHC (J–L) of wildtype (J), heterozygous (K), and homozygous (L) kidneys
demonstrate the presence of α2(I) chains in the vasculature of wildtype and heterozygous
kidneys, and the absence of anti-α2(I) positive staining within glomeruli of wildtype,
heterozygous, and homozygous kidneys. Asterisks indicate glomeruli.14
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Figure 11. Quantitative RT-PCR steady-state mRNA expression. COL1A1 (top) and
COL1A2 (bottom) transcripts in wildtype (+/+), heterozygous (+/−) and homozygous
(−/−) Col1a2- deficient glomeruli. 1-month and 3-month old homozygous glomeruli
demonstrate increases in proα1(I) collagen mRNA copy as compared to age-matched
wildtype and heterozygous glomeruli (*p <0.003 and *p <0.0001 respectively).
Proα2(I)collagen mRNA copy number decreases in 3-month old heterozygous (*p
<0.0001) and homozygous (*p <0.003) glomeruli as compared to age-matched wildtype
glomeruli.14
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Figure 12. MMP-2, -3, and -9 Quantitative RT-PCR. Demonstrates an increase in
MMP-2 (A), and MMP-3 (B) mRNA expression in 3-month Col1a2-deficient (−/−)
glomeruli compared to age-matched wildtype (+/+) [MMP-2, *p <0.0004; MMP-3,*p
<0.04]. MMP-3 (B) and MMP-9 (C) demonstrate significant increases between 1-month
and 3-month wildtype and Col1a2-deficient glomeruli [MMP-3, †p <0.04 Col1a2deficient glomeruli; MMP-9, †p <0.01 wildtype and MMP-9, †p <0.0007 Col1a2deficient glomeruli]. 1-month and 3-month Col1a2-deficient glomeruli show an increase
in MMP-2 (D) (*p ≤0.001 and *p ≤0.008 respectively), and MMP-3 (E) (*p ≤0.0005 and
*p ≤0.0003 respectively) protein expression as compared to age-matched wildtype mice,
while MMP-9 (F) shows a decrease in protein expression at three months of age (*p
≤0.05). Data expressed as mean ±SEM.14
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addition, mesangial cells are capable of producing type I collagen in response to
damage.30 Collagen deposition and renal injury has been shown to occur at one week of
age in the Col1a2-deficient mouse model.7 Transforming growth factor-b1 (TGF-b1) was
first studied to see if it is responsible in mediating this deposition. TGF-b1 has been
found to be upregulated in models of liver and kidney fibrosis. The effects of this
upregulation resulted in serum increases of this growth factor, as well as, increased
collagen deposition in the subendothelial space.31,32 It had previously been discovered
that TGF-b1 is released by mesangial cells under specific conditions.33 It has also been
shown to activate/stimulate mesangial cells.34 Upon activation these mesangial cells can
then differentiate into cells that exhibit myofibroblast-like phenotypes.35,36 TGF-b1 is
also suggested that TGF-b1 is capable of activating myfibroblastic cells37-40, the result of
which, is an increase in ECM accumulation and production. Matrix metalloproteinases
(MMPs) play a critical role in this progression, as they have been shown to activate TGFb1.34,41 This activation is correlated to TGF-b1 inducing epithelial-mesenchymaltransition (EMT) in multiple types of cancers: lungs, kidneys, liver, and prostate.42,43
EMT has been described as the loss of intercellular junctions, detachment of the
epithelium from the basement membrane, a decrease in epithelial protein markers, and an
increase of mesenchymal markers. Due to the increase in mesenchymal phenotype these
cells have the ability to traverse the basement membrane and differentiate into multiple
cell types. TGF-b1 is capable of inducing EMT in different renal fibrosis models through
a range of mediators.44 Markers of EMT are vimentin, desmin, and a-SMA.45 The
presence of myofibroblasts indicate that EMT could be occurring. Myofibroblasts have
the ability to contract and play a role in the wound healing response/process.44 The

23

process by which myofibroblasts are found in the renal mesangium has yet to be shown
but three postulations have been made. First, that myofibroblasts arise from
differentiation of epithelial cells in the renal intersitium and traverse the Bowman’s
capsule through breaks from previous damage. Second, is that myofibroblasts are formed
from mesangial cells due to the over expression of a-SMA triggering EMT. Third, is that
myofibroblasts arise from epithelial cells that make up the Bowman’s capsule itself and
when this happens the capsule begins to break down, thereby, releasing myofibroblasts
into the glomerular mesangium.46
It has been previously shown that proximal tubule cells undergo EMT and begin
expressing a-SMA when signaled by TGF-b. Additionally, the cytoskeleton around
these cells reorganizes into longitudinal bundles of fibers, which are referred to as
stress fibers. a-SMA gets incorporated into these stress fibers firmly securing the cell to
the extracellular matrix. Stress fibers are a characteristic associated with myofibroblast
formation and are used as an indicator for EMT.47,48
A study done in 2002 explored mesenchymal markers, their expression, and
collagen deposition in 133 biopsies from patients with renal disease. The study found that
the basement membrane, when intact, showed expression of vimentin in the tubular cells,
but not all tubular cells expressed a-SMA. For collagen, both type I and type III were
present in the tubular cells. Interstitial fibrosis and the number of tubular cells that
exhibited markers of EMT were directly related, and this was further shown to be in
direct correlation patient’s creatinine levels.49
Due to the findings of these studies and the potential role of TGF-b1 inducing
EMT it was postulated that TGF-b1 could be playing a role in activating EMT in the
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Col1a2-deficient mouse model leading to the deposition of homotrimeric type I collagen
in the renal mesangium. Col1a2-deficient mice were analyzed for presence and
localization of vimentin, desmin, a-SMA, and PCNA (Proliferating Cell Nuclear
Antigen) via IHC (Figure 13). PCNA is involved in proliferation of cells through its
localization to the nucleus where it is critical for DNA replication, however, upon cell
damage PCNA is ubiquitylated for degredation.50 Proliferation was evaluated through
PCNA labeling. Vimentin, desmin, and a-SMA were present and had a greater labeling
in the parietal epithelium of glomeruli of Col1a2-deficient mice (Figure 13 B&D, F&H,
J&L). The localization of these markers suggested that EMT was in fact occurring. The
localization and labeling of PCNA decreased in Col1a2-deficient mice, which could
indicate cell death or damage and a decrease in proliferation of mesangial cells (Figure 13
N&P). It could also be speculated that these cells are being displaced due to the
deposition of homotrimeric type I collagen in the renal mesangium and, are therefore,
being pushed to the periphery.51
mRNA and protein levels of TGF-b1 were not increased in Col1a2-deficient as
compared to wild type at one-month or three-months of age. Interestingly, TGF-b1
mRNA was actually reduced in Col1a2-deficient mice (Figure 14A). TGF-b1 protein
was not localized within the glomeruli of frozen or paraffin-embedded kidneys from
wild type, heterozygote, or Col1a2-deficient mice at one-month or three-months of age
when evaluated via IHC (Figure 14B).51
Therefore, it was concluded that TGF-b1/Smad3 was uninvolved in the early
stages of the disease through the comparison of scoring of Col1a2-deficient mice with
Col1a2-deficient/Smad3-deficient knockout mice at one-week of age. The absence of
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TGF-b1 via Smad3 signaling did not affect severity of the disease (Figure 15). It is
suggested that TGF-b1 signaling via Smad3 is not the primary initiator of homotrimeric
type I collagen deposition in the Col1a2-deficient model.51
Investigation into the Potential Role of TNF-a in Col1a2-deficient Mice
Another signaling pathway with a potential role in collagen accumulation in
Col1a2-deficient mice is tumor necrosis factor-a (TNF-a). TNF-a is a known
inflammatory cytokine that responds to damage or injury in tissue. Mesangial cells have
been shown to also release TNF-a upon exposure to various pathogens.52 Mesangialderived TNF-a has been suggested to be responsible for podocyte effacement.
Effacement of podocytes leads to proteinuria53 and complete podocyte loss.54 EMT in
multiple cancer types has also been shown to result from TNF-a signaling, including
renal cell carcinoma.55 TNF-a has also been shown to increase in plasma and urine of
individuals with diabetic nephropathy56 and primary nephrotic syndrome.57 Due to EMT
and mesangial cell proliferation caused by TNF-a it was hypothesized that TNF-a may
be responsible for homotrimeric type I collagen deposition in the Col1a2-deficient mouse
model.
The role of TNF-a was evaluated through the use of a known TNF-a inhibitor,
Etanercept. Etanercept is a fusion protein comprised of soluble TNF-a receptor (sTNF-a
receptor), and IgG antibody. The fusion acts as a competitive inhibitor of TNF-a.
Etanercept has a half-life five times longer than the endogenous sTNF-a receptor and has
an affinity for TNF-a 50-fold higher than the endogenous receptor. The result of this is
enhanced ability to bind TNF-a, thereby, reducing the pathogenic effects and improving

26

Figure 13. Col1a2-deficient (-/-) glomeruli demonstrate parietal epithelial cell (PEC)
EMT at 1-month of age. Immunostaining of 1-week and 1-month +/+ and -/- kidneys
with α-sma, Desmin, Vimentin, and PCNA. Immunostaining at 1-week of age
demonstrates glomerular α-sma (A, B), desmin (E, F), vimentin (I, J), and PCNA (M, N)
in both +/+ and -/- within the same regions, consistent with developmental expression. αsma is seen in the vascular pole of +/+ glomeruli (C); in contrast to -/- glomeruli (D),
which show α-sma staining in PECs and in the mesangium. At 1-month of age, +/+
kidneys demonstrate desmin (G) and vimentin (K) staining in podocytes while -/glomeruli demonstrate intense desmin (H) and vimentin (L) staining in PECs and a
redistribution of positive staining in podocytes to the periphery. PCNA positive staining
was seen in +/+ (O) and -/- (P) glomeruli at 1-month of age; however, there was a
decrease in intraglomerular staining and an increase in PEC positivity as compared to +/+
glomeruli.51
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Figure 14. TGF-β1 steady-state mRNA and protein are not upregulated in
homotrimeric type I collagen glomerulopathy. (A) Quantitative RT-PCR demonstrates
that TGF-β1 copy number is not significantly different in glomerular isolates of 1-month
old wildtype (+/+) and Col1a2-deficient (-/-) mice. However, by 3-months of age TGFβ1 copy number is elevated in wildtype glomerular isolates compared to 1-month +/+ and
1- and 3-months of age Col1a2-deficient glomerular isolates. (B) Although protein
immunoassay demonstrated no significant difference in picograms (pg) of TGF-β1
protein per glomerulus in wildtype (+/+) and Col1a2-deficient (-/-) glomeruli at both 1month and 3-month of age, Col1a2-deficient (-/-) glomeruli at 1-month of age exhibited a
greater variability in TGF-β1 protein per glomerulus.51
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Figure 15. Col1a2-deficient/Smad3-deficient glomeruli demonstrate homotrimeric
type I collagen deposition. (A) 1-month Col1a2-deficient glomerulus demonstrating
fibrillar collagen deposition upon staining with picrosirius red. (B) 1-month Smad3deficient glomeruli demonstrating similar intensity of picrosirius red staining. Mean
lesions scores for 1-month Col1a2-deficient/Smad3-deficient animals are provided in the
table (below) and demonstrate no significant differences.51
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symptoms of affected individuals.58
Investigation into the Potential Role of PDGF in Col1a2-deficient Mice
Platelet derived growth factor (PDGF) has been shown to be upregulated in most
renal diseases, play a role in mesangial proliferation and interstitial proliferation, and be
upregulated in response to renal injury/damage.59 PDGF ligands and receptors also play a
role in myofibroblast proliferation, collagen production, and promotion of cell adhesion.
These same ligands/receptors are regulated through ECM proteins and glycoproteins,
both of which are increased throughout the progression of fibrosis.60
Five hetero/homo-dimeric proteins, PDGF-AA, PDGF-BB, PDGF-AB, PDGFCC, and PDGF-DD classify the ligands of PDGF. There are three tyrosine kinase
receptors that these ligands interact with, PDGFR-aa, PDGFR-bb, and the less
characterized PDGFR-ab (Figure 16).61 PDGF-AA and -BB were the first to be
discovered59,62,63 with PDGF-CC and -DD being discovered later. PDGF-AA and -BB are
different than -CC and -DD, in that, PDGF-CC and -DD are secreted with an N-terminal
domain, known as a CUB (complement C1r/C1s, Uegf, Bmp1) domain. This domain
must be cleaved in order for the ligands to interact with their corresponding receptor.59,64
Auto phosphorylation occurs upon binding of ligands to their receptors, causing
dimerization of the receptors and downstream signaling.61
The pathways affected by PDGF ligands and their receptors include, but are not
limited to, rat sarcoma-mitogen-activated protein kinase (Ras-MAPK), phospholipase C-g
(PLC-g), and phosphatidyl-inositol-3-kinase (PI3K) (Figure 16). PDGF ligands and
receptors have been shown to play critical roles in the development of renal tissue in
mice.61 Ras-MAPK is highly conserved across species and has been shown to play a role
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in cellular proliferation, metabolism, differentiation, motility, apoptosis, and survival. In
addition, this signaling cascade is very complex and inducible through multiple different
mediators.65 PLC-g is less characterized than Ras-MAPK, however, PLC-g has been
shown in vivo to play a role in the development of the kidney.66 PI3K signals Akt/PKB, a
serine/threonine kinase. This pathway controls cell growth, proliferation, differentiation,
and survival, which is speculated to play a critical role in the development of fibrosis in
kidney disease.67
Early in mouse renal development, PDGF-AA, -BB, -CC, and -DD are
expressed.59 Knockout mice have been studied in great detail and have demonstrated the
imperative role of PDGF in the development of mice. Knockouts of PDGF-AA, -BB, CC, PDGFR-bb, and -aa, die prenatally or just after birth.59,68 PDGFR-aa knockouts
show a deficit in the renal mesenchyme, the consequences of which are abnormal
nephron development.69 Knockouts of PDGF-BB and its corresponding PDGFR-bb result
in malformation of the capillary tuft or capillary loops due to the lack of mesangial cells
that provide the structural scaffolding for capillaries. This results in an increase in
diameter of capillaries and a decrease in capillary organization. Mesangial cells are
critical for the organization, filtration efficiency, and surface area of glomerular
capillaries.70-72
The role of these ligands and receptors have been implicated in various forms of
disease pathways, including fibrosis and cancers. Smooth muscle cells and fibroblasts
respond to PDGF, leading to fibrosis and scarring in the lungs, liver, kidney, skin, and
heart.73 Chronic glomerulosclerosis has been shown to be driven by PDGF-BB and -DD
resulting in secondary tubulointerstitial fibrosis (TIF). It has been further shown that
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PDGF-DD has profibrotic outcomes on the tubular interstitium through the potential of
EMT. In glomeruli, mesangial cell proliferation has been shown to be induced through
the over production of PDGF-BB and -DD ligands via PDGFR-bb.74,75 Taken together
these effects indicate that PDGF is a key regulator of mechanisms that lead to fibrotic and
proliferative abnormalities in the kidney, more specifically, in the glomeruli of the
nephrons. A PDGF-DD knockout has yet to be characterized.61
PDGFR-aa is expressed in the renal insterstitium, smooth muscle cells, and
mesangial cells. Mesangial, parietal epithelial, and interstitial cells all express PDGFRbb, as well as, smooth muscle cells of the renal arteries. PDGF-AA has been observed in
epithelial cells and mature podocytes. The expression of PDGF-BB has for the most part
been hard to confirm via IHC, however, it has been shown in low levels within the renal
mesangium expressed by mesangial cells.76 Finally, in mice PDGF-DD has been
expressed, exclusively, by mesangial cells.61,77
In fibrotic models, especially in mice, it has been shown that the expression of
PDGFs, ligands and receptors, are upregulated.59 PDGF-CC has been shown to be
expressed in TIF areas on infiltrating macrophages and interstitial cells.76,78 PDGF-BB
has been widely studied and has been shown to be expressed on a wide variety of cells in
fibrotic models.59 Most importantly for our model, PDGF-BB is expressed in mesangial
cells and podocytes.59 PDGF-DD has been least characterized out of the PDGF ligands.61
Finally, PDGFR-bb is shown to be over expressed in fibrotic areas within the renal
mesangium and endothelial cells.59
Recent research has been done to assess the regulation via fucosylation of
PDGFR-bb and TGF-b1 receptor through an enzyme fucosyltransferase (FUT). While
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there are multiple FUTs, FUT8 was studied as it is responsible for the regulatory
mechanism of these two receptors. FUT8 knockdown (siRNA and shRNA) reduced the
prevalence of a-SMA in both PDGFR-bb and TGF-b1 receptor.79 This result could have
implications for the Col1a2-deficient mouse model and homotrimeric type I collagen
glomerulopathy.
Aims
The first aim of this study was to examine the effect of a TNF-α inhibitor in the
Col1a2-deficient mouse model using Etanercept, a known TNF-α inhibitor. The second
aim of this study was to determine if there is differential labeling, via IHC, of PDGF-BB,
PDGF-DD, and PDGFR-ββ in the Col1a2-deficient mouse model in comparison to the
wild type mice.
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Figure 16. Simplification of main molecules involved in PDGF-PDGFR interactions.
PDGF -AA, -AB, and -BB are secreted in an active form whereas PDGF -CC and -DD
have to be proteolytically cleaved to allow binding of the ligands to their receptors.
Proteases known to split off the PDGF-CUB domains are tPA or plasmin (PDGF-CC),
and uPA or MT- Sp1 (PDGF-DD). PDGF binding results in autophosphorylation of the
cytoplasmic tyrosine kinase domain of the PDGF receptor chains and subsequently
recruits adaptor proteins carrying Src homology 2 (SH2) and SH3 domains to this site.
Downstream signaling occurs mainly via the JAK/STAT, PI3K, PLC-γ, or RAS-MAPK
pathways, promoting gene expression and mediating the biological functions of the
PDGF isoforms, e.g. proliferation, migration, and survival. A highly relevant profibrotic
crosstalk is the cooperation of PDGF and integrin signaling. NHERFs were shown to link
PDGFR-β with focal adhesion kinase and the cortical actin cytoskeleton, thereby
enhancing PDGF-induced MAPK signaling. For simplification of the scheme, many other
regulatory processes, e.g., processes limiting the PDGF response, are not included but are
mentioned in the text. Also, not shown are transactivation processes of PDGFRs without
ligand binding by, e.g., G-protein-coupled receptors. PDGF, platelet-derived growth
factor, PDGFR PDGF receptor, CUB complement C1r/C1s, Uegf, Bmp1, tPA tissue-type
plasminogen activator, uPA urokinase-type plasminogen activator, MT-Sp1 matrip- tase,
ECM extracellular matrix, NHERF Na+/H+ exchanger regulatory factor, MERM merlin
and ezrin/radixin/moesin family of cytoskeletal linkers, FAK focal adhesion kinase, JAK
Janus kinase, STAT signal transducers and activators of transcription, PLC-γ
phospholipase C-γ, PI3K phosphatidyl-inositol-3-kinase, JNK c-Jun amino-terminal
kinase, RAS rat sarcoma, MAPK mitogen-activated protein kinase, Akt/PKB protein
kinase B, PKC protein kinase C, p70S6K ribosomal protein S6 kinase beta-1.61
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MATERIALS & METHODS

Picro Sirius Red (PSR) Staining
Paraffin embedded formalin fixed kidneys were sectioned at 5 microns. Picro
Sirius Red (PSR) stains for fibrillary collagen and the kit for this protocol was ordered
from Polysciences Inc. (Cat # 24901). The recommended procedure was followed.
Sections were depariffinized in xylene in increments of 3 minutes for three separate
washes. Sections were then placed in graded ethanol washes, starting at 100% three times
for three minutes. Each section was then set in 95% ethanol for 1 minute, then set in 70%
ethanol for one minute. The purpose of the graded ethanol washes is to rehydrate tissue.
Tissue sections were rinsed with distilled water for three minutes to prepare for staining.
Samples were placed in Solution A (Phosphomolybdic acid) for two minutes. This was
followed by a distilled water rinse before being placed in Solution B (Picrosirius red
F3BA stain) for 60 minutes. Solution C (0.1 N Hydrochloride acid) is the next solution
the tissue sections were set into for two minutes. The sections then go through graded
ethanol washes to dehydrate and prepare for mounting. This procedure started with 45
seconds in 75% ethanol, followed by a one-minute wash in 95% ethanol, and finally
placed in 100% ethanol for three minutes. Lastly, Permount is applied to the slides so that
cover slips can be added. Slides were left to dry overnight and were visualized the next
day via light microscopy.
Tissue and Histology (TNF-a)
The following mice were cared for according to protocol at the University Of
Connecticut. The mice were injected intravenously with saline or Etanercept (5ug/g
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bodyweight) twice weekly for 6 weeks, then sacrificed just over a week after the final
dose. Kidneys from male and female wildtype and Col1a2-deficient mice were used and
divided into four previous determined categories: wildtype mice treated with the vehicle
(IgG1), wildtype mice treated with Etanercept (a TNF-a inhibitor), Col1a2deficient mice treated with vehicle, and treated Col1a2-deficient mice using Etanercept.
These kidneys were evaluated for the presence of fibrillar collagen deposition and given a
lesion score (M0 through M4) to represent the severity of the deposition. Kidney blocks
were received from Charlotte L. Phillips, PhD at the University of Missouri.
Tissues were prepared by IDEXX BioResearch in Columbia, MO using standard
formalin fixation and paraffin embedding procedure. In all, 37 kidneys were sectioned in
a longitudinal fashion measuring 7µm in thickness using a Leica RM2135 microtome on
the Missouri State University campus. These samples were taken from seven-week old
wildtype and Col1a2-deficient mice. The sections were then mounted on positivelycharged slides, labeled, and placed on a covered slide warmer for 30 minutes to dry.
After, they were placed in a slide box and stored in a refrigerator at 4ºC for later use.
Lesion Scoring (TNF-a)
Sections were examined via conventional light microscopy to evaluate the
presence of collagen within glomeruli of Col1a2-deficient mice in comparison to wild
type mice. Lesion scoring is based on the severity of collagen that is present within
glomeruli and the scoring is as follows: G0 – no lesioning, G1 – mild lesions with less
than 25% of the glomeruli affected, G2 – moderate lesions with less than 50% of the
glomeruli affected, G3 – moderately lesioned and affects less than 75% of the glomeruli,
and G4 – severely lesioned and affects greater than 75% of the glomeruli.7.
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Morphometry Mapping
Morphometry mapping utilizes the lesion scoring system described above.
Morphometry scores are obtained by counting multiple fields (10x) of glomeruli and
giving each one a lesion score. The scores are added up taking into account the total
glomeruli count with its corresponding lesion score 0-4. An example equation is supplied
below. [(0x#)+(1x#)+(2x#)+(3x#)+(4x#)] ÷ Total number of glomeruli counted. (#)
represents the number of glomeruli counted for each possible lesion score number, 0-4.7
Histology (PDGF)
Tissues were prepared by IDEXX BioResearch in Columbia, MO using standard
formalin fixation and paraffin embedding procedure. Five wild type mice (2259, 2252,
2192, 2214, 2218) and five Col1a2-deficient mice (2253, 2229, 2265, 2255, 2183) were
chosen. These kidneys were sectioned in a longitudinal fashion measuring 5µm in
thickness using a Leica RM2135 microtome on the Missouri State University campus.
These samples were taken from six-week old wild type and Col1a2-deficient mice. The
sections were then mounted on positively-charged slides, labeled, and placed on a
covered slide warmer for 30 minutes to dry. After, they were placed in a slide box and
stored in a refrigerator at 4ºC for later use.
Immunohistochemical (IHC) Labeling (PDGF)
Protocol, antibodies, and blocking reagent were bought and received from Santa
Cruz Biotechnology. Indirect Immunoperoxidase Staining was performed per
manufacturers’ guidelines. Formalin-fixed, paraffin-embedded mice kidneys were used
for sectioning via a microtome. Sections were cut at 5 microns. Antigen retrieval was
achieved through a sodium citrate boil. This allowed for antigens to be unmasked and
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ready for indirect immunoperoxidase staining. Blocking reagent(UltraCruzâ Blocking
Reagent, sc-516214) was used to mask any unwanted antigens that the primary antibody
may have a low affinity for, thereby increasing the binding of the primary to the target.
After blocking sections for 1-hour, primary antibodies were diluted in blocking reagent
and added to sections. They were allowed to sit overnight in 4o C. In the morning
secondary antibody were added, diluted in blocking reagent, for two hours. Sections were
then incubated with SIGMAFAST 3,3’-Diaminobenzidene (DAB) (D4293-50SET),
ordered from SIGMA Life Sciences, for 10 minutes in a dark room. Sections were
dehydrated with increasing graded ethanol washes, finishing in xylene and were then
counterstained with hematoxylin for nuclei staining. Permount was used to mount
coverslips on the kidney section slides. Primary antibodies include: PDGF-BB (F-3) sc365805, mouse monoclonal IgG2b 200 ug/ml, PDGFR-bb (D-6) sc-374573, mouse
monoclonal IgG2a 200 ug/ml, PDGF-DD (E-7) sc-137029, mouse monoclonal IgG2a
200ug/ml. Primary antibodies were diluted (1:100) in UltraCruzâ Blocking Reagent and
secondary antibodies were diluted (1:50) in UltraCruzâ Blocking Reagent. Secondary
antibody was a Horse Radish Peroxidase (HRP) conjugated antibody: m-IgGK BP-HRP,
sc-516102, HRP conjugated 200 ug/05.ml.
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RESULTS

Tumor Necrosis Factor – Alpha
The first aim of this study was to examine the effect of a TNF-α inhibitor in the
Col1a2-deficient mouse model using Etanercept, a known TNF-α inhibitor. The goal of
this aim was to determine if TNF-a is the primary mediating molecule in homotrimeric
type I collagen glomerulopathy in the Col1a2-deficient mouse model. Etanercept is a
TNF-a inhibitor used to diminish TNF-a effects in this study. It was hypothesized that
Col1a2-deficient mice treated with Etanercept would show attenuated PSR positive
staining in comparison to Col1a2-deficient mice treated with vehicle.
Six-week-old male and female wildtype and Col1a2-deficient mice were used to
test TNF-a. The four different groups were as follows: wild type mice treated with
vehicle (IgG1), wild type mice treated with Etanercept, Col1a2-deficient mice treated
with vehicle (IgG1), and finally, Col1a2-deficent mice treated with Etanercept.
As has been shown previously, there was no homotrimeric type I collagen
deposition in wild type mice treated with vehicle (IgG1) (Figure 17) or in the wild type
mice treated with Etanercept (Figure 18). There was an observed uptake of PSR stain
within the glomerulus of Col1a2-deficient mice that were treated with vehicle (IgG1), as
expected (Figure 19). Col1a2-deficient mice treated with Etanercept also demonstrated
PSR positive staining (Figure 20). Based on these results, it was concluded that
Etanercept treatment was not eliminating fibrosis.
To determine if treatment was decreasing fibrosis in Col1a2-deficient mice
morphometry mapping7 was performed. Also, lesion severity was quantified among the
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four groups. Mean lesion scores for all genotypes can be seen in Table 2. Mean lesion
scores for wildtype mice treated with the vehicle was zero while those treated with
Etanercept was 0.046 ± 0.038. The mean lesion score for Col1a2-deficient mice that were
treated with the vehicle was 3.197 ± 0.191, indicating on average, glomeruli were more
than 50% filled with collagen. The mean lesion score for Col1a2-deficient mice treated
with Etanercept was 2.799 ± 0.170, this also indicated that on average, glomeruli were
greater than 50% collagenated with mild lesioning. The mean lesion score difference
between the Col1a2-deficient groups was 0.398 ± 0.256 with a p-value of 0.432. There is
not a statistically significant difference in lesion scoring severity between Col1a2deficient mice who received the vehicle and in those who received the treatment.80 These
results indicated that TNF-a is not the primary mediating molecule in homotrimeric type
I collagen glomerulopathy in Col1a2-deficient mice.
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Figure 17. Deposition of Type I Collagen in Untreated Wildtype Mice. Wildtype mice
treated with the vehicle IgG and stained with Picrosirius Red. Arrows indicate
glomeruli.80
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Figure 18. Deposition of Type I Collagen in Treated Wildtype Mice. Wildtype mice
treated with the TNF-alpha inhibitor, Etanercept and stained with Picrosirius Red.
Arrows indicate glomeruli.80
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Figure 19. Deposition of Type I Collagen in Untreated Col1a2-deficient Mice.
Col1a2-deficient mice treated with IgG and stained with Picrosirius Red. As expected,
there is significant deposition of collagen within the glomeruli. Mean lesion score for
affected mice was 3.196 with a p-value of 0.432. Mean difference is significant at the
p<0.05 level. Arrows indicate glomeruli. Asterisks indicate moderately severe (G3) to
severely (G4) affected and PSR positive glomeruli.80

43

Figure 20. Deposition of Type I Collagen in Treated Col1a2-deficient Mice. Col1a2deficient mice treated with Etanercept and stained with Picrosirius Red. Visually,
glomeruli appear to be filled with similar collagen depositions as those treated with the
vehicle despite TNF-a inhibition. Mean lesion score for affected mice was 2.799 with a
p-value of 0.432. Mean difference is significant at the p<0.05 level. Arrows indicate
glomeruli. Asterisks indicate moderately severe to severely affected and PSR positive
glomeruli.80
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Table 2. Mean Lesion Score for Wild Type and Col1a2-deficient Mice.80
Mean Lesion Score
Wildtype +
vehicle

Wildtype +
Etanercept

Col1a2deficient +
vehicle

Col1a2deficient +
Etanercept

Wildtype +
vehicle

0

0.046 ±
0.038

3.197 ±
0.191

2.799 ±
0.170

0.000

Wildtype +
Etanercept

0.046 ±
0.038

0

3.151 ±
0.195

2.753 ±
0.174

0.000

Col1a2deficient +
vehicle

3.197 ±
0.191

3.151 ±
0.195

0

0.398 ±
0.256

0.432

Col1a2deficient +
Etanercept

2.799 ±
0.170

2.753 ±
0.174

0.398 ±
0.256

0

0.432

Genotype
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p-value

Platelet Derived Growth Factor – Receptor bb, Ligand -BB, Ligand -DD
The second aim of this study was to determine if there is differential labeling, via
IHC, of PDGF-BB, PDGF-DD, and PDGFR-ββ in the Col1a2-deficient mouse model in
comparison to the wild type mice. The goal of this aim was to determine if PDGF is the
primary mediating molecule in homotrimeric type I collagen glomerulopathy in the
Col1a2-deficient mouse model. It was hypothesized that PDGFR-bb, PDGF-BB, and
PDGF-DD would show increased labeling in Col1a2-deficient mice in comparison to
their wild type counterparts.
Six-week-old male and female wild type (+/+) and Col1a2-deficient (-/-) mice
were used for this study. Five wild type (+/+) and five Col1a2-deficient (-/-) mice were
chosen and used for PSR and all IHC runs. Consistent with previous studies, the Col1a2deficient mice (-/-) showed homotrimeric type I collagen deposition within glomeruli and
no deposition in that of their wild type (+/+) counterparts when evaluated via PSR
staining (Figure 21). A morphometry score was assigned to each Col1a2-deficient (-/-)
mouse and is seen in the upper left-hand corner of each section image, with morphometry
scores range from 1.8-3.0 (Figure 21). PSR was performed to compare the severity of
morphometry score to the intensity of labeling, via IHC, for the different PDGF isoforms.
PDGFR-bb labeling via IHC showed differential labeling of Col1a2-deficient
mice (-/-) in comparison to wild type mice (+/+) with localization of labeling occurring in
the renal mesangium or in the renal epithelium, i.e. podocytes (Figure 22). There was an
even distribution of stain evenly spaced throughout the glomeruli in the Col1a2-deficient
mice (-/-) with little, if any stain present in the wild type mice (+/+) (Figure 22). For
Col1a2-deficient mice (-/-), morphometry score increases from left to right (Figure 21)
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and labeling of PDGFR-bb also increases from left to right (Figure 22). The glomeruli
with morphometry score 1.8 (Figure 21) and the corresponding glomeruli in Figure 22
(top row, far left) has the least labeling for PDGFR-bb. This is contrasted by the
glomeruli with a morphometry score of 3.0 (Figure 21) and its corresponding glomeruli
in Figure 22 (top row, far right) has the greatest amount of labeling for PDGFR-bb.
These results suggest a positive correlation between morphometry score (lesioning) and
the presentation of PDGFR-bb.
PDGF-BB labeling via IHC showed differential labeling of Col1a2-deficient mice
(-/-) in comparison to wild type mice (+/+) with localization of labeling occurring in the
renal mesangium or in the renal epithelium, i.e. podocytes (Figure 23). There is stain
even distribution throughout the glomeruli in the Col1a2-deficient mice (-/-) with little if
any, stain present in the wild type mice (+/+). For Col1a2-deficient mice (-/-),
morphometry score increases from left to right (Figure 21) and labeling of PDGF-BB
also increases from left to right (Figure 23). This is shown by the glomeruli with a
morphometry score of 3.0 (Figure 21) and its corresponding glomeruli in Figure 23 (top
row, far right) has the greatest amount of labeling for PDGF-BB. These results may
represent a relationship between morphometry score (lesioning) and the presentation of
PDGF-BB.
PDGF-DD labeling of Col1a2-deficient mice (-/-) in comparison to their wild type
counterparts (+/+) was less conclusive. There was labeling in both Col1a2-deficient mice
(-/-) and wild type mice (+/+) (Figure 24). There was less correlation of morphometry
score (Figure 21) and the intensity of labeling for PDGF-DD (Figure 24). For example,
the glomeruli with morphometry score 2.3 and 2.9 (Figure 21) mild-severe lesioning had
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the greatest amount of stain for PDGF-DD (Figure 24), but the glomeruli corresponding
to the morphometry score 3.0 glomeruli had less stain (Figure 24). The inconsistency of
labeling in the Col1a2-deficient mice (-/-) along with the presentation of stain in wild
type mice (+/+) make the findings for PDGF-DD inconclusive. There does not seem to be
a correlation between morphometry score and intensity of labeling (Figure 21 and 24) or
differential labeling when comparing Col1a2-deficient mice (-/-) to that of their wild type
counterparts (+/+) (Figure 24).
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Figure 21. Picrosirius Red (PSR) Stain of Five Wild Type and Five Col1a2-deficient
Mice. The top row corresponds to the five Col1a2-deficient mice (-/-) and the bottom row
corresponds to the five wild type mice (+/+). A morphometry score was given to the
sections 2183, 2265, 2229, 2253, and 2255. Their associated morphometry scores are 1.8,
2.3, 2.6, 2.9, and 3.0 respectively. Wild type mice are not given a morphometry because
no collagen is present within wild type glomeruli.
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Figure 22. 40x Magnification of PDGFR-bb Labeling in Glomeruli of Wild Type
and Col1a2-deficient Mice. The top row corresponds to the five Col1a2-deficient mice (/-) and the bottom row corresponds to the five wild type mice (+/+). Order of Col1a2deficient (-/-) mice corresponds to the order in Figure 22 (2183, 2265, 2229, 2253, and
2255).
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Figure 23. 40x Magnification of PDGF-BB Labeling in Glomeruli of Wild Type and
Col1a2-deficient Mice. The top row corresponds to the five Col1a2-deficient mice (-/-)
and the bottom row corresponds to the five wild type mice (+/+). Order of Col1a2deficient (-/-) mice corresponds to the order in Figure 22 (2183, 2265, 2229, 2253, and
2255).
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Figure 24. 40x Magnification of PDGF-DD Labeling in Glomeruli of Wild Type and
Col1a2-deficient Mice. The top row corresponds to the five Col1a2-deficient mice (-/-)
and the bottom row corresponds to the five wild type mice (+/+). Order of Col1a2deficient (-/-) mice corresponds to the order in Figure 22 (2183, 2265, 2229, 2253, and
2255).
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Discussion

Tumor Necrosis Factor – alpha
Tumor Necrosis Factor-alpha (TNF-α) was assessed as a possible contributor to
this homotrimeric type I collagen glomerulopathy. As expected, no collagen deposition
was seen in wildtype animals consistent with previous work. There is evidence of
significant collagen deposition in both Col1a2-deficient treated (Etanercept) and
untreated models (Vehicle IgG). After statistical analysis, there was no significant
difference between Col1a2-deficient mice that received treatment (Etanercept) and
Col1a2-deficient mice that received vehicle (IgG). There were also no significant changes
in wildtype mice that received treatment (Etanercept) and wild type mice that received
vehicle (IgG). The conclusion of this study was that Etanercept did not affect lesioning
within glomeruli, therefore, TNF-α was not the main mediator of collagen deposition in
the renal mesangium in the Col1a2-deficient mouse model.
A limitation of this study is that collagen in this model is present as early as twoweeks of age in Col1a2-deficient mice and Etanercept was administered twice weekly for
six-weeks. With the progressiveness of homotrimeric type I collagen glomerulopathy,
Etanercept treatment, may not have been sufficient in diminishing this response. Previous
studies have demonstrated that the collagen deposition seen in our model occurs postnatally and as early as two-weeks of age.7 This study provides insight at the six-week
mark, long after the deposition is known to ensue.80
Inflammation is a main even leading to the production and increase of serum
TNF-α levels, as well as other cytokines. Furthermore, TNF-α is a proinflammatory
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molecule that has activation effects on endothelial cells and activation of multiple
cytokines.81 It has also been shown that TNF-α/TNFR inhibition with neutralizing
antibodies and soluble TNFR can decrease protein urea in anti-GBM rat models.82 In the
Col1a2-deficient inflammation does not occur as would normally occur in fibrotic
conditions. This is a potential limitation as TNF-α/TNFR pathways are characterized by
their known proinflammatory effects in fibrosis.
In addition, collagen deposition in bone has been shown to be disrupted by TNFα. This is due to downregulation in lysyl oxidase, an enzyme responsible for forming
crosslinks in type I collagen chains. TNF-α is thereby regulating collagen deposition with
little effect on the synthesis of the heterotrimer.83 Interestingly enough, our model for
Col1a2-deficient mice exclusively produce homotrimeric type I collagen. Therefore, it
could be suggested that TNF-α is responsible in decreased deposition of the heterotrimer
but not the homotrimer or has diminished effects on homotrimeric type I collagen.
Platelet-Derived Growth Factor
PDGFR-bb, PDGF-BB, and PDGF-DD were evaluated to determine the primary
mediators of homotrimeric type I collagen glomerulopathy. It was found, as in previous
studies, that homotrimeric collagen deposition is occurring in Col1a2-deficient mice
when evaluated via PSR. Furthermore, it was also found, as in previous studies, that no
homotrimeric type I collagen is being deposited in wild type mice. Evaluation of labeling
via IHC showed differential labeling for PDGFR-bb and PDGF-BB, contrasted by less
conclusive labeling for PDGF-DD. PDGF-DD was the only stain present in glomeruli of
wild type mice. Morphometry mapping, assessed via PSR, correlated to IHC labeling
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intensity for PDGFR-bb and PDGF-BB, but was unrelated in the labeling via IHC for
PDGF-DD.
Differential labeling for the different isoforms of PDGF would be expected when
comparing wild type mice to that of their Col1a2-deficient counterparts. This is due to the
involvement of PDGF in renal disease, proliferation, cell survival, cell migration, and the
production of ECM.61 The collagen deposition seen in Col1a2-deficient mice is
hypothesized as a result of the secondary wound healing response as the body responds to
kidney injury or damage.7 PDGF has been shown to be upregulated in many forms of
renal fibrotic mouse models61 therefore, it is suggested that it would also be upregulated
in the Col1a2-deficient mouse model. Further study is needed to definitively say if
PDGF-receptor/ligand interaction is the main mediator of collagen deposition in the
Col1a2-deficient mouse model, thereby, being the main mediator of the secondary wound
healing response.
A new study looks at fucosylation as a potential mediator of renal fibrosis as it
has been shown to regulate alpha-smooth muscle actin (a-SMA), a known marker of
myofibroblast proliferation, thereby, an indicator of fibrosis.
Core Fucosylation Regulation – PDGF & TGF-b1
Fucosylation is the process by which fucose groups are added to N-terminal
glycans on receptors by enzymes known as fucosyltransferase (FUT) (Figure 4 in
Appendix).
A recent study in 2017 looked at FUT8 knockdowns via siRNA and shRNA to see
if their regulation had implications on fibrotic effects of unilateral uretal obstruction
(UUO) mouse models, specifically regulation of PDGF-receptors and TGF-b1
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receptors.79 Their results show that they could alleviated a-SMA expression and
myofibroblastic morphological changes in pericytes upon knockdown of FUT8 (Figure
1A&B in Appendix). Furthermore, it was shown that siRNA for FUT8 could successfully
knockdown FUT8/LCA expression (Figure 1C in Appendix).79
Histological examination of tissue in this study also showed UUO fibrotic tissue
in UUO day seven mice, however, when these mice were treated with siRNA for FUT8
tissue was dramatically less scarred and damaged (Figure 2A in Appendix). It was further
shown, via immunofluorescence that a-SMA could be alleviated upon induction with
siRNA for FUT8 (Figure 2B in Appendix).79 Finally, they did a protein quantification for
PDGF and TGF-b1 receptors along with their downstream mediators ERK and smad2/3
respectively. It was shown that immunoprecipitated LCA bound to both receptors was
down regulated in mice treated with siRNA for FUT8, as well as, a decrease in the
downstream mediators for both receptors (Figure 3 in Appendix).79
Future Directions
Further investigation is required to assess the role of TNF-a in the early stages of
homotrimeric type I collagen glomerulopathy in Col1a2-deficient mice, as well as, the
potential correlation between epithelial-to-mesenchymal transition and TNF-a in Col1a2deficient mice. A limitation of this TNF-a study was the age and dryness of kidney
sections, therefore, it is suggested that further experiments be done to confirm the
findings reported on this study. This could include RT-PCR for mRNA transcripts of
TNF-a and western blotting to see if there is differential expression of mRNA and
protein in comparison of wild type mice and that of their Col1a2-deficient counterparts.
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The initial results from IHC for PDGFR-bb, PDGF-BB, and PDGF-DD show
promise as potentially leading to homotrimeric type I collagen glomerulopathy, however,
RT-PCR will need to be performed to confirm expression of mRNA for PDGFR-bb,
PDGF-BB, and PDGF-DD, as well as, Western blot for PDGFR-bb, PDGF-BB, and
PDGF-DD to confirm if protein expression is upregulated in response to mRNA. This
may need to be followed up by a study of PDGF-AA, PDGF-CC, and PDGFR-aa as
well.
Finally, a new study has shown how regulation of core fucosylation can have
effects on a-SMA expression, PDGFR activation, and TGF-b1 receptor activation.69 It
would be interesting to apply core fucosylation regulation to the Col1a2-deficient mouse
model to see if PDGF receptor and TGF-b1 receptor activation is synergistically leading
to homotrimeric type I collagen glomerulopathy in the Col1a2-deficient mouse model.
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APPENDIX

Figure A1. Core fucosylation was down-regulated and the pericyte-myofibroblast
transition was inhibited upon FUT8 knockdown in vitro. Primary cultures of
pericytes were incubated with TGFβ1 (10 ng/ml) for 24 or 48 h. (a) Representative
bright-field images of morphological changes in pericytes, where black arrows indicate
pericytes, and representative images of FUT8 (green), LCA (green), and α-SMA (red)
staining are shown. Quantification is shown in the lower panel. (b) FUT8 and α-SMA
levels were assessed using Western blot analyses. Quantification is shown in the lower
panel. (c) Lectin blot analyses. Cell lysates were subjected to a lectin blot analysis
using LCA. Representative data are shown. Quantification is shown in the lower panel.
Scale bar, 50 µm. *P < 0.01, † P < 0.01. * and † indicate the comparison of the control
group with the TGFβ1 group; # indicates the comparison of the FUT8 knockdown
group with the TGFβ1 group.79
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Figure A2. The pericyte-myofibroblast transition was inhibited and RIF was
reduced upon FUT8 knockdown in vivo. UUO models were established (n = 5). A
recombinant adenovirus carrying the FUT8 shRNA was used to knock down FUT8
expression in vivo. (a) Representative images of Masson’s trichrome-stained and PASstained UUO kidney sections. (b) Representative images of dual staining for PDGFRβ
(green) and α-SMA (red) staining and dual staining for PDGFRβ (green) and CD31
(red). Quantification of α-SMA staining is shown in the lower panel. Scale bar, 50 µm.
*P < 0.01, # P < 0.01. *Indicates the comparison of the control group with the UUO
group; #indicates the comparison of the FUT8 knockdown group with the UUO
group.79
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Figure A3. Core fucosylation regulates the pericyte-myofibroblast transition
through both the TGFβ/Smad2/3 and PDGF/ERK1/2 pathways in vitro. (a)
TGFβR1 and PDGFRβ levels in total cell lysates were assessed using Western blot
analyses. Lectin blot analysis of the immunoprecipitated TGFβR1 and PDGFRβ
proteins. TGFβR1 and PDGFRβ were immunoprecipitated from whole cell lysates
with anti-TGFβR1 and anti-PDGFRβ antibodies, respectively. The blots were probed
with LCA. Representative data are shown. Quantification is shown in the lower panel.
(b) Smad2/3, p-Smad2/3, ERK1/2, and p-ERK1/2 levels were assessed using Western
blot analyses. Total cell lysates were subjected to immunoblotting. Representative data
are shown. Quantification is shown in the lower panel. *P < 0.01, # P < 0.01. *
and † indicate the comparison of the control group with the TGFβ1 group; # indicates
the comparison of the FUT8 knockdown group with the TGFβ1 group.79
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Figure A4. Core fucosylation regulates transforming growth factor b (TGF-b) and
platelet-derived growth factor (PDGF) signaling pathways in the pathophysiology of
peritoneal fibrosis. Core fucosylation is a common posttranslational modification of key
receptors of these signaling pathways, including both TGF-b and PDGF receptors
(PDGFRs). Glucose peritoneal dialysis (PD) fluid upregulates core fucosylation,
promoting the a-1,6 fucosyltransferase (Fut8) to fucosylate the extracellular domains of
TGF-b and PDGF receptors, activate TGF-b/ Smad2/3 and PDGF/ERK signaling, and
subsequently induce extracellular matrix deposition, leading to peritoneal fibrosis. Fut8
short hairpin RNA (shRNA) significantly attenuated peritoneal fibrosis in a rat model of
peritoneal fibrosis via abrogating core fucosylation of the TGF-b and PDGF receptors.
ALK5, activin receptor-like kinase 5; F, fucose; p, phosphorylated; TGF-bRII, TGF-b
receptor II.84
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